Principles and Methods of Intervention Research

Size: px
Start display at page:

Download "Principles and Methods of Intervention Research"

Transcription

1 Principles and Methods of Intervention Research NVVO, February 2, 2009 Jan G.P. Tijssen, Ph.D. Academic Medical Center - University of Amsterdam

2 Introduction Pathophysiologic and pharmacological insight Theory or hypothesis about efficacy of a medical intervention Clinical studies to evaluate clinical usefulness Randomised clinical trial has become the paradigm

3 Clinical decisions Balancing of the magnitude of the Expected therapeutic benefit (= Intended effects) Adverse effects (= Unintended effects) Costs

4 Clinical Trial A means for measuring expected therapeutic benefit

5 Example

6 BMCR trial Patients Previously untreated metastatic colorectal cancer Investigative Treatment Bevacizumab or placebo Background Treatment Irinotecan, Fluorouracil, Leucovorin (IFL) Outcome Median Survival Time (MST)

7 Results BMCC trial

8 Results BMCC trial Treatment #PTS MST Surv-1y Bevacizumab % Placebo % Treatment benefit Improvement in median survival 4.7 mo Improvement in 1-year survival 10.9% Hazard Ratio for death 0.66 MST = Median survival time (months)

9 HIVEX trial

10 HIVEX trial Patients Adenocarcinoma of the mid-to-distal esophagus or of the gastric cardia involving the distal esophagus Treatment Transthoracic esophagectomy with extended en bloc lymphadenectomy Transhiatal esophagectomy Outcome Median Survival Time (MST)

11 Results HIVEX trial

12 Results HIVEX trial Treatment #PTS Rate* Transthoracal % Transhiathal % Treatment benefit Improvement in 5-year survival 10% Improvement in median survival 4 mo *at 5 years

13 Measurement device Object of measurement Measurement errors Systematic errors Random errors

14 Object of measurement Treatment effect (Only meaningful in relative terms) The disease entity (condition, indication) Treatments to be compared The disease outcome (clinical course)

15 Disease entity (1) In / exclusion criteria Disease Recruitment scheme Patients with the disease Patient characteristics Clinical spectrum Patients 'represent' the disease at issue

16 Outcomes BMCC Primary outcome Overall survival Secondary Outcome Progression-free survival Response rate Duration of response Safety Quality of life

17 Outcomes HIVEX Primary outcome Overall survival & disease-free survival Secondary Outcome Early morbidity & mortality Quality-adjusted life-years Cost-effectiveness

18 Ordering of outcome parameters Primary outcomes Secondary outcomes

19 Primary outcome parameter One single parameter related to primary objective Identified in advance Specified in objective of the trial Related to study size calculation Determines positive/negative trial

20 Secondary outcome parameters Other parameters relating to efficacy Provide supportive evidence May generate hypotheses

21 Measurement errors Accurate measurement Lack of systematic error Internal validity Precise measurement Lack of random error Precision is based on the size of the treatment groups

22

23 Lack of systematic errors When index treatment is as effective as as reference treatment No differences except for random variation Principles of study design derive from the need to avoid systematic errors.

24 Results BMCC trial Treatment #PTS MST Surv-1y Bevacizumab % Placebo % Treatment benefit Improvement in median survival 4.7 mo Improvement in 1-year survival 10.9% Hazard Ratio for death 0.66 MST = Median survival time (months)

25 Influential factors Extraneous factors Attention of the physician Psychology of patient Adjustment life style Decisions about other treatments Prognostic factors Risk profile of the patients Information about outcome Investigative treatment

26 Methods Masking of treatment Patient & treating physician (primary process) Placebo, double dummy, independent physician Randomization Random assignment of study treatment Blinding Blinding of outcome assessor

27 Comparison OC 1 OC 0 EF 1 = EF 0 NC 1 = NC 0 IE 1 = IE 0 Masking / Placebo Randomization Blinding of assessor TE

28 Functionality Masking (of patient & physician to treatment) Comparability of extraneous factors Randomization Comparability of groups (prognosis) Blinding of outcome assessor Comparability of information on outcome

29 Drug trials in oncology Masking of treatments is important Other treatments given must be the same! Wellbeing of patient Adverse effects may prevent masking. Randomization is key Blinded assessment of the outcome is consequence of masking

30 Results HIVEX trial Treatment #PTS Rate* Transthoracal % Transhiatal % Treatment benefit Improvement in 5-year survival 10% Improvement in median survival 4 mo *at 5 years

31 HIVEX trial Comparison of strategies No extraneous factors Everything is part of either procedure Comparability of extraneous factors is not an issue Open trial design Randomization is key Blinded assessment of the outcome is critical

32 Extraneous factors What aspect of the investigational treatment is to be studied? Focus on chemical substance Masking (placebo) is necessary Focus on procedure as a whole (strategy) Open comparison of strategies

33 Random assignment Purpose Removes investigator selection bias Comparability of known and unknown risk factors Validity of statistical techniques Concealed treatment allocation No knowledge whatsoever in advance about the treatment assignment of a particular patient.

34 Implementation of randomization In open trial Telephone /computer allocation mandatory Envelopes or lists are subject to tampering Immediate registration by fax or internet Only with double-blind pre-packed medication Systematic randomization is no randomization

35 Comparability of information Information bias (or detection bias) must be avoided Biased patient reporting Biased ascertainment of information by physician Biased assessment of information by physician, data manager, statistician BLINDING of outcome assessment

36 Double-blind versus open In 'classical' double blind trial blinding is consequence of masking (placebo). In open trial 'comparability of information' is a separate issue.

37 Withdrawals Discontinuation of treatment Cross-over to other treatment Non-fatal event Poor compliance Adverse experiences No outcome information

38 HIVEX trial 109/114 & 93/106 patients underwent the randomized procedure. 4 patients in each group did not have adenocarcinoma in the resection specimen. All patients were analyzed in randomized group.

39 Withdrawal Usually related to clinical cause Jeopardizes comparability of natural course Infringes on result of randomization Solutions Intention-to-treat analysis Last observation carried forward (LOCF)

40 Results BMCC trial Treatment #PTS MST Surv-1y Bevacizumab % Placebo % Treatment benefit Improvement in median survival 4.7 mo Improvement in 1-year survival 10.9% Hazard Ratio for death 0.66 MST = Median survival time (months)

41 Intention-to-treat analysis Principle Outcomes are available in all patients Outcomes are counted according to original randomization, irrespective of actual treatment Consequence Dilution of treatment effects Similar to ordinary clinical practice Preferred method in mortality trials

42 Intention-to-treat analysis Principle Outcomes are available in all patients Outcomes are counted according to original randomization, irrespective of actual treatment Consequence Dilution of treatment effects Similar to ordinary clinical practice Preferred method in mortality trials

43 Availability of Outcomes Yes No Intention-to-treat analysis possible Ad hoc solutions Worse case imputation Leaving patients out from the analysis Missing outcomes must be avoided!

44 Measurement device Object of measurement Measurement errors Systematic errors Random errors

45 Precision Outcomes are subject to random variation Precision = random variation in observed effect estimate Precision is quantified via confidence interval

46 Results HIVEX trial Treatment #PTS Rate* Transthoracal % Transhiathal % Improvement in 5-year survival 10% 95% Confidence Interval (-3%, 23%) * KM at 5 years

47 95%-confidence interval Range of values surrounding point estimate Interval estimate of the treatment effect Contains true RR in 95% of the applications 95% confident that true RR is embraced

48 Conclusion HIVEX

49 Results BMCC trial Treatment #PTS MST Surv-1y Bevacizumab % Placebo % Improvement in median survival 4.7 mo 95% confidence interval? P-value < MST = Median survival time (months)

50 Conclusion BMCC

51 Width of 95%-CI Depends on size of treatment groups Small studies have wide CIs Carry little information Large studies have narrow CIs Carry much information

The RoB 2.0 tool (individually randomized, cross-over trials)

The RoB 2.0 tool (individually randomized, cross-over trials) The RoB 2.0 tool (individually randomized, cross-over trials) Study design Randomized parallel group trial Cluster-randomized trial Randomized cross-over or other matched design Specify which outcome is

More information

How to improve the reliability of Single Arm Trials

How to improve the reliability of Single Arm Trials Workshop on Single Arm Trials in Oncology Products EMA, London, June 30, 2016 How to improve the reliability of Single Arm Trials Paolo Bruzzi Clinical Epidemiology Unit IRCCS San Martino-IST - National

More information

CONSORT 2010 checklist of information to include when reporting a randomised trial*

CONSORT 2010 checklist of information to include when reporting a randomised trial* CONSORT 2010 checklist of information to include when reporting a randomised trial* Section/Topic Title and abstract Introduction Background and objectives Item No Checklist item 1a Identification as a

More information

EBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University

EBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University EBM: Therapy Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University How to appraise therapy literature Are the result valid? What are the result?

More information

The comparison or control group may be allocated a placebo intervention, an alternative real intervention or no intervention at all.

The comparison or control group may be allocated a placebo intervention, an alternative real intervention or no intervention at all. 1. RANDOMISED CONTROLLED TRIALS (Treatment studies) (Relevant JAMA User s Guides, Numbers IIA & B: references (3,4) Introduction: The most valid study design for assessing the effectiveness (both the benefits

More information

PhD Course in Biostatistics

PhD Course in Biostatistics PhD Course in Biostatistics Univ.-Prof. DI Dr. Andrea Berghold Institute for Medical Informatics, Statistics and Documentation Medical University of Graz andrea.berghold@medunigraz.at Content Introduction

More information

Determining the Optimal Surgical Approach to Esophageal Cancer

Determining the Optimal Surgical Approach to Esophageal Cancer Determining the Optimal Surgical Approach to Esophageal Cancer Amit Bhargava, MD Attending Thoracic Surgeon Department of Cardiovascular and Thoracic Surgery Open Esophagectomy versus Minimally Invasive

More information

Change in 28 HRQL outcomes after open surgery, open surgery combined, and minimally invasive surgery at 3, 6, 9, and 12 months follow-up.

Change in 28 HRQL outcomes after open surgery, open surgery combined, and minimally invasive surgery at 3, 6, 9, and 12 months follow-up. Supporting information for Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer. Online Resource 1 Online Resource 2 Online Resource

More information

Critical Appraisal Practicum. Fabio Di Bello Medical Implementation Manager

Critical Appraisal Practicum. Fabio Di Bello Medical Implementation Manager Critical Appraisal Practicum Fabio Di Bello Medical Implementation Manager fdibello@ebsco.com What we ll talk about today: DynaMed process for appraising randomized trials and writing evidence summaries

More information

GATE CAT Intervention RCT/Cohort Studies

GATE CAT Intervention RCT/Cohort Studies GATE: a Graphic Approach To Evidence based practice updates from previous version in red Critically Appraised Topic (CAT): Applying the 5 steps of Evidence Based Practice Using evidence about interventions

More information

Randomized Controlled Trial

Randomized Controlled Trial Randomized Controlled Trial Training Course in Sexual and Reproductive Health Research Geneva 2016 Dr Khalifa Elmusharaf MBBS, PgDip, FRSPH, PHD Senior Lecturer in Public Health Graduate Entry Medical

More information

Safinamide (Addendum to Commission A15-18) 1

Safinamide (Addendum to Commission A15-18) 1 IQWiG Reports Commission No. A15-41 Safinamide (Addendum to Commission A15-18) 1 Addendum Commission:A15-41 Version: 1.1 Status: 29 October 2015 1 Translation of addendum A15-41 Safinamid (Addendum zum

More information

Review. A. Di Leo 1 *, M. Buyse 2 & H. Bleiberg 1. Introduction. Design and main results of the trials

Review. A. Di Leo 1 *, M. Buyse 2 & H. Bleiberg 1. Introduction. Design and main results of the trials Review Annals of Oncology 15: 545 549, 2004 DOI: 10.1093/annonc/mdh127 Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical

More information

CRITICAL APPRAISAL OF MEDICAL LITERATURE. Samuel Iff ISPM Bern

CRITICAL APPRAISAL OF MEDICAL LITERATURE. Samuel Iff ISPM Bern CRITICAL APPRAISAL OF MEDICAL LITERATURE Samuel Iff ISPM Bern siff@ispm.unibe.ch Contents Study designs Asking good questions Pitfalls in clinical studies How to assess validity (RCT) Conclusion Step-by-step

More information

Issues to Consider in the Design of Randomized Controlled Trials

Issues to Consider in the Design of Randomized Controlled Trials Issues to Consider in the Design of Randomized Controlled Trials Jay Wilkinson, MD, MPH Professor of Pediatrics & Epidemiology Miller School of Medicine Seminar Purpose To facilitate an interactive discussion

More information

Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym

Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents* Section/item Item No Description Addressed on page number Administrative information Title 1 Descriptive

More information

Possible causes of difference among regions How to look at the results from MRCT Non-compliance with GCP and/or protocol Apparent Differences (Play of

Possible causes of difference among regions How to look at the results from MRCT Non-compliance with GCP and/or protocol Apparent Differences (Play of Outline ICH E17 General Principles for Planning and Design of Multi-Regional Clinical Trials Future MRCTs Based on E17 Guideline Background and Key Principles in E17 Some case studies of Gastric Cancer

More information

Quantitative research Quiz Answers

Quantitative research Quiz Answers Quantitative research Quiz Answers 1. What is a clinical trial? A. A clinical trial is an experiment where patients volunteer to test new ways of screening for, preventing, diagnosing or treating a disease.

More information

Surgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours?

Surgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours? Surgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours? Question #2: How are cardia tumours managed? Michael F. Humer December 3, 2005 Vancouver, BC Case

More information

Checklist for appraisal of study relevance (child sex offenses)

Checklist for appraisal of study relevance (child sex offenses) Appendix 3 Evaluation protocols. [posted as supplied by author] Checklist for appraisal of study relevance (child sex offenses) First author, year, reference number Relevance Yes No Cannot answer Not applicable

More information

CLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM

CLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM CLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM Principles of Decision Making Knowing the patient s true state is often unnecessary Does my patient

More information

User s guide to the checklist of items assessing the quality of randomized controlled trials of nonpharmacological treatment

User s guide to the checklist of items assessing the quality of randomized controlled trials of nonpharmacological treatment User s guide to the checklist of items assessing the quality of randomized controlled trials of nonpharmacological treatment Reviewers will answer the following items, taking into account the data repted

More information

How to carry out health technology appraisals and guidance. Learning from the Scottish experience Richard Clark, Principal Pharmaceutical

How to carry out health technology appraisals and guidance. Learning from the Scottish experience Richard Clark, Principal Pharmaceutical The Managed Introduction of New Medicines How to carry out health technology appraisals and guidance. Learning from the Scottish experience Richard Clark, Principal Pharmaceutical Analyst July 10 th 2009,

More information

RATING OF A RESEARCH PAPER. By: Neti Juniarti, S.Kp., M.Kes., MNurs

RATING OF A RESEARCH PAPER. By: Neti Juniarti, S.Kp., M.Kes., MNurs RATING OF A RESEARCH PAPER RANDOMISED CONTROLLED TRIAL TO COMPARE SURGICAL STABILISATION OF THE LUMBAR SPINE WITH AN INTENSIVE REHABILITATION PROGRAMME FOR PATIENTS WITH CHRONIC LOW BACK PAIN: THE MRC

More information

Delfini Evidence Tool Kit

Delfini Evidence Tool Kit General 1. Who is sponsoring and funding the study? What are the affiliations of the authors? Study Design Assessment Internal Validity Assessment Considerations: This can be helpful information and is

More information

Experimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial

Experimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial Experimental Design Chusak Okascharoen, MD, PhD September 19 th, 2016 Terminology Experimental study Clinical trial Randomized controlled trial 1 PHASES OF CLINICAL TRIALS Phase I: First-time-in-man studies

More information

ARE THE RESULTS VALID?

ARE THE RESULTS VALID? ARE THE RESULTS VALID? At the beginning, did intervention and control groups start with the same prognosis? Was randomization process adequate? Was randomization concealed? Were patients in the study groups

More information

Contents. Version 1.0: 01/02/2010 Protocol# ISRCTN Page 1 of 7

Contents. Version 1.0: 01/02/2010 Protocol# ISRCTN Page 1 of 7 Contents 1. INTRODUCTION... 2 2. STUDY SYNOPSIS... 2 3. STUDY OBJECTIVES... 2 3.1. Primary Objective... 2 3.2. Secondary Objectives... 2 3.3. Assessment of Objectives... 3 3.4. Change the Primary Objective

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie

More information

Bevacizumab is currently licensed for the following indication relevant for this NICE review:

Bevacizumab is currently licensed for the following indication relevant for this NICE review: Roche Executive Summary Context Bevacizumab (Avastin) is a humanized (93% human) murine monoclonal antibody which binds to and neutralizes VEGF, a powerful pro-angiogenic glycoprotein produced by both

More information

The role of Randomized Controlled Trials

The role of Randomized Controlled Trials The role of Randomized Controlled Trials Dr. Georgia Salanti Lecturer in Epidemiology University of Ioannina School of Medicine Outline Understanding study designs and the role of confounding Observational

More information

How to Interpret a Clinical Trial Result

How to Interpret a Clinical Trial Result How to Interpret a Clinical Trial Result Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine Rochester MN CP123456-1 Are results

More information

Everolimus for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT

Everolimus for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT Thank you very much for the opportunity to submit additional analysis in relation to the above technology appraisal

More information

An introduction to Quality by Design. Dr Martin Landray University of Oxford

An introduction to Quality by Design. Dr Martin Landray University of Oxford An introduction to Quality by Design Dr Martin Landray University of Oxford Criteria for a good trial Ask an IMPORTANT question Answer it RELIABLY Quality Quality is the absence of errors that matter to

More information

ARCHE Risk of Bias (ROB) Guidelines

ARCHE Risk of Bias (ROB) Guidelines Types of Biases and ROB Domains ARCHE Risk of Bias (ROB) Guidelines Bias Selection Bias Performance Bias Detection Bias Attrition Bias Reporting Bias Other Bias ROB Domain Sequence generation Allocation

More information

Evaluating Effectiveness of Treatments. Elenore Judy B. Uy, M.D.

Evaluating Effectiveness of Treatments. Elenore Judy B. Uy, M.D. Evaluating Effectiveness of Treatments Elenore Judy B. Uy, M.D. OUTLINE 1. Why evaluate effectiveness 2. How to acquire evidence 3. How to appraise evidence Directness Validity Results 4. Our Case WALA

More information

Critical Review Form Therapy Objectives: Methods:

Critical Review Form Therapy Objectives: Methods: Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To

More information

Panel Two: Evidence for Use of Maintenance Therapy

Panel Two: Evidence for Use of Maintenance Therapy Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued

More information

Critical Appraisal Series

Critical Appraisal Series Definition for therapeutic study Terms Definitions Study design section Observational descriptive studies Observational analytical studies Experimental studies Pragmatic trial Cluster trial Researcher

More information

Maxing out on quality appraisal of your research: Avoiding common pitfalls. Policy influenced by study quality

Maxing out on quality appraisal of your research: Avoiding common pitfalls. Policy influenced by study quality Maxing out on quality appraisal of your research: Avoiding common pitfalls. WITH EXAMPLES FROM THE ONGOING SETS RCT STUDY ERIC PARENT, PT, M.SC. PH.D. ASSOCIATE PROFESSOR,DEPT. OF PHYSICAL THERAPY AND

More information

Protocol Development: The Guiding Light of Any Clinical Study

Protocol Development: The Guiding Light of Any Clinical Study Protocol Development: The Guiding Light of Any Clinical Study Susan G. Fisher, Ph.D. Chair, Department of Clinical Sciences 1 Introduction Importance/ relevance/ gaps in knowledge Specific purpose of the

More information

Further data analysis topics

Further data analysis topics Further data analysis topics Jonathan Cook Centre for Statistics in Medicine, NDORMS, University of Oxford EQUATOR OUCAGS training course 24th October 2015 Outline Ideal study Further topics Multiplicity

More information

Current standard in treatment of peritoneal carcinomotisis. Data behind the HIPEC trials

Current standard in treatment of peritoneal carcinomotisis. Data behind the HIPEC trials Current standard in treatment of peritoneal carcinomotisis Data behind the HIPEC trials Overview Peritoneal carcinomatosis STANDARD treatment HIPEC Results of treatment Counter side of treatment Peritoneal

More information

Critical Review Form Therapy

Critical Review Form Therapy Critical Review Form Therapy A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects, Lancet-Neurology 2007; 6: 953-960 Objectives: To evaluate the effect of

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Howard R, McShane R, Lindesay J, et al. Donepezil and memantine

More information

Supporting information for Systematic review reveals limitations of studies evaluating health-related quality of life after potentially curative

Supporting information for Systematic review reveals limitations of studies evaluating health-related quality of life after potentially curative Supporting information for Systematic review reveals limitations of studies evaluating health-related quality of life after potentially curative treatment for esophageal cancer Supplement Material 1 Supplement

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of

More information

Randomized Clinical Trials

Randomized Clinical Trials Randomized Clinical Trials p. 1/42 Randomized Clinical Trials Hematology/Oncology Lecture Series Elizabeth G. Hill, PhD Associate Professor of Biostatistics 17 November 2011 Randomized Clinical Trials

More information

Checklist for Randomized Controlled Trials. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews

Checklist for Randomized Controlled Trials. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews Checklist for Randomized Controlled Trials http://joannabriggs.org/research/critical-appraisal-tools.html www.joannabriggs.org

More information

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Annual Rheumatology & Therapeutics Review for Organizations & Societies Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research

More information

Guidelines for Reporting Non-Randomised Studies

Guidelines for Reporting Non-Randomised Studies Revised and edited by Renatus Ziegler B.C. Reeves a W. Gaus b a Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Great Britain b Biometrie und Medizinische Dokumentation,

More information

Module 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town

Module 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town Module 5 The Epidemiological Basis of Randomised Controlled Trials Landon Myer School of Public Health & Family Medicine, University of Cape Town Introduction The Randomised Controlled Trial (RCT) is the

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist.

Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:

More information

Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227

Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to

More information

GLOSSARY OF GENERAL TERMS

GLOSSARY OF GENERAL TERMS GLOSSARY OF GENERAL TERMS Absolute risk reduction Absolute risk reduction (ARR) is the difference between the event rate in the control group (CER) and the event rate in the treated group (EER). ARR =

More information

Critical Appraisal of RCT

Critical Appraisal of RCT Critical Appraisal of RCT What is critical appraisal? Definition Process of systematically examining research evidence to assess its reliability (validity/internal validity), results and relevance (external

More information

Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial

Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial Gastric Cancer (219) 22:369 376 https://doi.org/1.7/s112-18-875-1 ORIGINAL ARTICLE Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial

More information

4. Aflibercept showed significant improvement in overall survival (OS), the primary

4. Aflibercept showed significant improvement in overall survival (OS), the primary Cost effectiveness of aflibercept (Zaltrap ) in combination with FOLFIRI in the treatment of adult patients with metastatic colorectal cancer (mcrc) that is resistant to or has progressed after an oxaliplatin

More information

Health authorities are asking for PRO assessment in dossiers From rejection to recognition of PRO

Health authorities are asking for PRO assessment in dossiers From rejection to recognition of PRO UNDERSTANDING AND ADDRESSING POTENTIAL BIAS IN PATIENT-REPORTED OUTCOMES FROM CLINICAL TRIALS ISPOR Barcelona Workshop Tuesday 13 November 14:00-15:00 Prof. Olivier Chassany EA 7334, Patient-Centered Outcomes

More information

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab

More information

ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine

ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000

More information

Types of Data. Systematic Reviews: Data Synthesis Professor Jodie Dodd 4/12/2014. Acknowledgements: Emily Bain Australasian Cochrane Centre

Types of Data. Systematic Reviews: Data Synthesis Professor Jodie Dodd 4/12/2014. Acknowledgements: Emily Bain Australasian Cochrane Centre Early Nutrition Workshop, December 2014 Systematic Reviews: Data Synthesis Professor Jodie Dodd 1 Types of Data Acknowledgements: Emily Bain Australasian Cochrane Centre 2 1 What are dichotomous outcomes?

More information

Clinical Trials. Introduction + guidance on proposals

Clinical Trials. Introduction + guidance on proposals Clinical Trials Introduction + guidance on proposals Open Information Day, Brussels, 29 May 2012 Cornelius Schmaltz Medical Research Unit Directorate Health Research & Innovation DG European Commission

More information

Cochrane Pregnancy and Childbirth Group Methodological Guidelines

Cochrane Pregnancy and Childbirth Group Methodological Guidelines Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews

More information

CONSORT: missing missing data guidelines, the effects on HTA monograph reporting Yvonne Sylvestre

CONSORT: missing missing data guidelines, the effects on HTA monograph reporting Yvonne Sylvestre CONSORT: missing missing data guidelines, the effects on HTA monograph reporting Yvonne Sylvestre Clinical Trials Methodology Conference, 5 th of October 2011 NWORTH North Wales Organisation for Randomised

More information

Limited en bloc Resection of the Gastroesophageal Junction with Isoperistaltic Jejunal Interposition

Limited en bloc Resection of the Gastroesophageal Junction with Isoperistaltic Jejunal Interposition 22 Limited en bloc Resection of the Gastroesophageal Junction with Isoperistaltic Jejunal Interposition J.R. Izbicki, W.T. Knoefel, D. C. Broering ] Indications Severe dysplasia in the distal esophagus

More information

Critical Review Form Therapy

Critical Review Form Therapy Critical Review Form Therapy Does End-tidal Carbon Dioxide Monitoring Detect Respiratory Events Prior to Current Sedation Monitoring Practices, Acad Emerg Med 2006; 13:500-504 Objective: To determine the

More information

SETTING Fudan University Shanghai Cancer Center. RESPONSIBLE PARTY Haiquan Chen MD.

SETTING Fudan University Shanghai Cancer Center. RESPONSIBLE PARTY Haiquan Chen MD. OFFICIAL TITLE A Phase Ⅲ Study of Left Side Thoracotomy Approach (SweetProcedure) Versus Right Side Thoracotomy Plus Midline Laparotomy Approach (Ivor-Lewis Procedure) Esophagectomy in Middle or Lower

More information

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s): Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer

TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive

More information

Horizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma

Horizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology

More information

Online Supplementary Material

Online Supplementary Material Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control

More information

Clinical Trials. Susan G. Fisher, Ph.D. Dept. of Clinical Sciences

Clinical Trials. Susan G. Fisher, Ph.D. Dept. of Clinical Sciences Clinical Trials Susan G. Fisher, Ph.D. Dept. of Clinical Sciences When to Do a RCT Exposure of interest is modifiable and individuals are willing to relinquish control Legitimate uncertainty exists about

More information

Out of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence)

Out of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence) Membranous nephropathy role of cyclosporine therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. The use of cyclosporine therapy alone to prevent progressive

More information

Systematic review with multiple treatment comparison metaanalysis. on interventions for hepatic encephalopathy

Systematic review with multiple treatment comparison metaanalysis. on interventions for hepatic encephalopathy Systematic review with multiple treatment comparison metaanalysis on interventions for hepatic encephalopathy Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with severe

More information

Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD)

Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) The NCPE has issued a recommendation regarding the cost-effectiveness of tolvaptan (Jinarc

More information

lab exam lab exam Experimental Design Experimental Design when: Nov 27 - Dec 1 format: length = 1 hour each lab section divided in two

lab exam lab exam Experimental Design Experimental Design when: Nov 27 - Dec 1 format: length = 1 hour each lab section divided in two lab exam when: Nov 27 - Dec 1 length = 1 hour each lab section divided in two register for the exam in your section so there is a computer reserved for you If you write in the 1st hour, you can t leave

More information

Management of Esophageal Cancer: Evidence Based Review of Current Guidelines. Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center

Management of Esophageal Cancer: Evidence Based Review of Current Guidelines. Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center Management of Esophageal Cancer: Evidence Based Review of Current Guidelines Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center Case Presentation 68 y/o male PMH: NIDDM, HTN, hyperlipidemia, CAD s/p stents,

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

Glossary of Practical Epidemiology Concepts

Glossary of Practical Epidemiology Concepts Glossary of Practical Epidemiology Concepts - 2009 Adapted from the McMaster EBCP Workshop 2003, McMaster University, Hamilton, Ont. Note that open access to the much of the materials used in the Epi-546

More information

Exploring and Validating Surrogate Endpoints in Colorectal Cancer. Center, Pittsburgh, USA

Exploring and Validating Surrogate Endpoints in Colorectal Cancer. Center, Pittsburgh, USA Page 1 Exploring and Validating Surrogate Endpoints in Colorectal Cancer Tomasz Burzykowski, PhD 1,2, Marc Buyse, ScD 1,3, Greg Yothers PhD 4, Junichi Sakamoto, PhD 5, Dan Sargent, PhD 6 1 Center for Statistics,

More information

The Cardiac Arrythmia Suppression Trial

The Cardiac Arrythmia Suppression Trial The Cardiac Arrythmia Suppression Trial 1 The Cardiac Arrythmia Suppression Trial Background and significance Methods Statistical Analysis Results Discussion Summary on Therapy 2 Background and significance

More information

Instrument for the assessment of systematic reviews and meta-analysis

Instrument for the assessment of systematic reviews and meta-analysis Appendix II Annex II Instruments for the assessment of evidence As detailed in the main body of the methodological appendix (Appendix II, "Description of the methodology utilised for the collection, assessment

More information

CRITICAL APPRAISAL WORKSHEET 1

CRITICAL APPRAISAL WORKSHEET 1 For Residents CRITICAL APPRAISAL WORKSHEET 1 AN ARTICLE ON THERAPY This worksheet should be submitted along with the completed Submission Form to your supervisor. It is based on the articles on therapy

More information

ACR OA Guideline Development Process Knee and Hip

ACR OA Guideline Development Process Knee and Hip ACR OA Guideline Development Process Knee and Hip 1. Literature searching frame work Literature searches were developed based on the scenarios. A comprehensive search strategy was used to guide the process

More information

Use of Sacubitril/Valsartan in Heart Failure

Use of Sacubitril/Valsartan in Heart Failure Use of Sacubitril/Valsartan in Heart Failure & the PARADIGM-HF trial Sarah Mackenzie, PharmD student, University of Toronto Presentation Outline Overview of: Entresto PARADIGM-HF trial Critical Appraisal

More information

Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial

Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial Xin Huang 1 and Qiang (Casey) Xu 2 1 Pfizer Oncology

More information

Assessing risk of bias

Assessing risk of bias Assessing risk of bias Norwegian Research School for Global Health Atle Fretheim Research Director, Norwegian Institute of Public Health Professor II, Uiniversity of Oslo Goal for the day We all have an

More information

Understanding Clinical Trials

Understanding Clinical Trials Understanding Clinical Trials HR =.6 (CI :.51.7) p

More information

UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA

UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation

More information

Incorporating Clinical Information into the Label

Incorporating Clinical Information into the Label ECC Population Health Group LLC expertise-driven consulting in global maternal-child health & pharmacoepidemiology Incorporating Clinical Information into the Label Labels without Categories: A Workshop

More information

CTRI Dataset and Description

CTRI Dataset and Description CTRI Dataset and Description CTRI Field Description Public title of study Title intended for the lay public in easily understood language. Example: A clinical trial to study the effects of two drugs, ramipril

More information

Role of Primary Resection for Patients with Oligometastatic Disease

Role of Primary Resection for Patients with Oligometastatic Disease GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko

More information

intent treatment be in the elderly?

intent treatment be in the elderly? Gastric cancer: How strong can curative intent treatment be in the elderly? Caio Max S. Rocha Lima, M.D. Professor of Medicine University of Miami & Sylvester Cancer Center Gastric cancer: epidemiology

More information

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival

More information

HARM. Definition modified from the IHI definition of Harm by the QUEST Harm Workgroup

HARM. Definition modified from the IHI definition of Harm by the QUEST Harm Workgroup Indonesia Clinical epidemiology and Evidence Based Medicine (ICE(ICE-EBM) HARM Jarir At Thobari (FK UGM) Efficacious Medical intervention Harm HARM Unintended physical injury resulting from or contributed

More information

IQWiG Reports Commission No. A Regorafenib

IQWiG Reports Commission No. A Regorafenib IQWiG Reports Commission No. A15-43 Regorafenib Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Regorafenib Nutzenbewertung

More information

PROSPERO International prospective register of systematic reviews

PROSPERO International prospective register of systematic reviews PROSPERO International prospective register of systematic reviews Prophylactic cranial irradiation in patients with non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled

More information

Guidance for Industry

Guidance for Industry Reprinted from FDA s website by Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R1) U.S. Department

More information